×
Synaptogenix EBITDA 1970-1969 | SNPX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Synaptogenix ebitda from 1970 to 1969. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Synaptogenix EBITDA 1970-1969 | SNPX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Synaptogenix ebitda from 1970 to 1969. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$241.7B
Amgen (AMGN)
$155.8B
Gilead Sciences (GILD)
$149.1B
Vertex Pharmaceuticals (VRTX)
$101.5B
Bristol Myers Squibb (BMY)
$97.4B
CSL (CSLLY)
$86.1B
GSK (GSK)
$79.8B
Regeneron Pharmaceuticals (REGN)
$59.5B
Alnylam Pharmaceuticals (ALNY)
$56.7B
Argenex SE (ARGX)
$39.6B
BioNTech SE (BNTX)
$27.1B
Insmed (INSM)
$26B
Royalty Pharma (RPRX)
$20.5B
Biogen (BIIB)
$19.8B
Incyte (INCY)
$16.8B
Illumina (ILMN)
$15.5B
Genmab (GMAB)
$14.5B
Genmab (GNMSF)
$14.3B
Ascendis Pharma (ASND)
$11.7B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$10.9B
Moderna (MRNA)
$10.5B
Exelixis (EXEL)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Verona Pharma American Depositary Share (VRNA)
$9B
Bio-Techne Corp (TECH)
$8.6B
Exact Sciences (EXAS)
$8.5B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8.1B
Halozyme Therapeutics (HALO)
$8B